Results 11 to 20 of about 351,938 (393)
Methotrexate in the urine [PDF]
Kidney International, 2011 A 62-year-old man with a recent diagnosis of primary central nervous system lymphoma developed acute kidney injury (AKI) after administration of high-dose methotrexate. AKI developed within 48 h of therapy despite prior infusion of intravenous bicarbonate solution. Serum methotrexate level was 2.61 μmol/l at 24 h and 0.25 μmol/l 72 h after methotrexate
Michael W. Ross, Sandeep K. Mallipattu
openaire +3 more sources
Journal of Ophthalmic and Vision Research, 2021 Intravitreal methotrexate (MTX) has been proven to be an effective treatment for various intraocular diseases. In this article, a comprehensive review was performed on intravitreal applications of methotrexate. Different aspects of the administration of intravitreal MTX for various clinical conditions such as intraocular tumors, proliferative ...
Fatemeh Abdi +2 more
openaire +4 more sources
International Journal of Molecular Sciences, 2020 Methotrexate, a structural analogue of folic acid, is one of the most effective and extensively used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune diseases.
P. Koźmiński +3 more
semanticscholar +1 more source
Methotrexate and Pralatrexate [PDF]
Dermatologic Clinics, 2015 This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides, Sézary syndrome, and CD30+ lymphoproliferative disorders. Although these folate antagonists are traditionally viewed as antiproliferative cell cycle inhibitors, it is recognized that they ...
Jianqiang Wu, Gary S. Wood
openaire +2 more sources
Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients [PDF]
, 2016 Purpose: Methotrexate administration is associated with frequent adverse neurological events during treatment for childhood acute lymphoblastic leukemia.
Baird, Susan F. +5 more
core +2 more sources
Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events
New England Journal of Medicine, 2019 BACKGROUND Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin‐1β, resulted in a lower rate of cardiovascular events than placebo in a previous ...
P. Ridker +25 more
semanticscholar +1 more source
, 2021 Introduction: Methotrexate, a folate antimetabolite, immunosuppressant and cytotoxic chemotherapeutic agents employed for malignant conditions. Continuous exposure of methotrexate produces adverse side effects especially liver toxicity.
Preetha Santhakumar +4 more
semanticscholar +1 more source
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. [PDF]
, 2004 BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind,
Close, DR +7 more
core +1 more source
Methotrexate and rheumatoid arthritis associated interstitial lung disease
European Respiratory Journal, 2020 Question addressed by the study Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA.
P. Juge +57 more
semanticscholar +1 more source
Clinics, 2016 OBJECTIVE: To test the hypothesis that intravenous use of methotrexate associated with lipid nanoemulsions can achieve superior anti-inflammatory effects in the joints of rabbits with antigen-induced arthritis compared with commercial methotrexate ...
Suzana B.V. Mello +4 more
doaj +1 more source